HealthDay - MONDAY, Sept. 10 (HealthDay News) -- Little more than one in eightphase II cancer clinical trials with encouraging results go forward to thelarger, phase III stage that's needed to bring a new therapy to patients,a new study finds.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.